HC Wainwright Has Negative Outlook of IPA Q1 Earnings

Key Points

• HC Wainwright has lowered its Q1 2026 earnings estimate for ImmunoPrecise Antibodies to ($0.04) per share, down from a prior estimate of ($0.03), while maintaining a "Buy" rating and a target price of $5.00.
• ImmunoPrecise reported Q1 earnings of ($0.04) per share, missing analysts' expectations of ($0.02) and generating $5.06 million in revenue, below the consensus estimate of $7.89 million.
• Wall Street Zen has updated its rating for ImmunoPrecise Antibodies to "sell," reflecting concerns about the company's financial performance and outlook.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2026 earnings estimates for ImmunoPrecise Antibodies in a research report issued to clients and investors on Wednesday, July 30th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.04) for the quarter, down from their previous estimate of ($0.03). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies' current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies' Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.04) EPS, FY2027 earnings at $0.04 EPS and FY2030 earnings at $0.25 EPS.

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). ImmunoPrecise Antibodies had a negative return on equity of 40.62% and a negative net margin of 122.10%. The business had revenue of $5.06 million during the quarter, compared to the consensus estimate of $7.89 million.

Separately, Wall Street Zen raised ImmunoPrecise Antibodies to a "sell" rating in a report on Saturday, May 24th.

ImmunoPrecise Antibodies Stock Performance

Shares of NASDAQ IPA opened at $1.66 on Friday. The company has a quick ratio of 2.11, a current ratio of 2.08 and a debt-to-equity ratio of 0.49. The firm's 50-day moving average price is $1.20 and its two-hundred day moving average price is $0.70. ImmunoPrecise Antibodies has a 52-week low of $0.27 and a 52-week high of $2.41. The stock has a market capitalization of $75.97 million, a P/E ratio of -2.44 and a beta of 0.44.

Hedge Funds Weigh In On ImmunoPrecise Antibodies

A hedge fund recently bought a new stake in ImmunoPrecise Antibodies stock. Baader Bank Aktiengesellschaft bought a new stake in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 26,961 shares of the company's stock, valued at approximately $29,000. Baader Bank Aktiengesellschaft owned 0.06% of ImmunoPrecise Antibodies as of its most recent SEC filing. 6.70% of the stock is owned by institutional investors.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.